THE ARISING · Longevity & Healthspan
A newer Moderna COVID shot was linked to fewer hospitalizations in older veterans
A VA study found an adjusted difference of about two COVID hospitalizations per 10,000 people. Hospitalization was uncommon with both vaccines.
Among 294,499 U.S. veterans aged 65 and older in a matched observational study, those who received Moderna’s mRNA-1283 vaccine had fewer COVID hospitalizations than those who received Pfizer–BioNTech’s BNT162b2 vaccine. Both shots were formulated for the LP.8.1 strain during the 2025–26 season. The researchers followed participants for up to 150 days.
The primary outcome was COVID that led to medical care, including antiviral treatment. It occurred in 86 of 55,349 people who received the Moderna shot (0.16%) and 672 of 239,150 people who received the Pfizer shot (0.28%). After adjustment, the estimated difference was 10 fewer cases per 10,000 people, equivalent to a 35.9% lower relative risk (95% credible interval, 20.4% to 49.7%).
Hospitalization was a secondary outcome. There were 11 COVID hospitalizations in the Moderna group (0.02%) and 114 in the Pfizer group (0.05%). After adjustment, the difference was 2.2 fewer hospitalizations per 10,000 people (95% credible interval, 0.2 to 3.8 fewer), or a 47.0% lower relative risk. The relative estimate was imprecise, and some alternative analyses were compatible with no difference.
The study did not assign people to vaccines at random. Even after matching and adjustment, differences between the groups could explain some of the result. Some outcomes the vaccines were not expected to affect also differed between groups. Moderna helped fund the research, and company employees took part in the study. The population was predominantly male, and the findings reflect a single respiratory-virus season.
The distinction between relative and absolute risk matters. A 47% difference sounds large, but very few people in either group were hospitalized. This comparison is useful evidence for older adults like those studied; it does not establish that one shot will outperform the other in every population or season.